

Selected Bibliography

- D. A. Ahlquist, H. S. Wieand, C. G. Moertel, D. B. McGill, C. L. Loprinzi, M. J. O'Connell, J. A. Mailliard, J. B. Gerstner, K. Pandya, and R. D. Ellefson. Accuracy of fecal occult blood screening for colorectal neoplasia. A prospective study using Hemocult and HemoQuant tests. *JAMA* 269 (10):1262-1267, 1993.
- K. S. Albain, S. R. Green, A. S. Lichter, L. F. Hutchins, W. C. Wood, I. C. Henderson, J. N. Ingle, J. O'Sullivan, C. K. Osborne, and S. Martino. Influence of patient characteristics, socioeconomic factors, geography, and systemic risk on the use of breast-sparing treatment in women enrolled in adjuvant breast cancer studies: an analysis of two intergroup trials. *J.Clin.Oncol.* 14 (11):3009-3017, 1996.
- E. Au, C. L. Loprinzi, M. Dhodapkar, T. Nelson, P. Novotny, J. Hammack, and J. O'Fallon. Regular use of a verbal pain scale improves the understanding of oncology inpatient pain intensity. *J.Clin.Oncol.* 12 (12):2751-2755, 1994.
- R. M. Auchter, D. Scholtens, S. Adak, H. Wagner, D. F. Cella, and M. P. Mehta. Quality of life assessment in advanced non-small-cell lung cancer patients undergoing an accelerated radiotherapy regimen: report of ECOG study 4593. Eastern Cooperative Oncology Group. *Int.J.Radiat.Oncol.Biol.Phys.* 50 (5):1199-1206, 2001.
- D. L. Barton, C. L. Loprinzi, S. K. Quella, J. A. Sloan, M. H. Veeder, J. R. Egnor, P. Fidler, P. J. Stella, D. K. Swan, N. L. Vaught, and P. Novotny. Prospective evaluation of vitamin E for hot flashes in breast cancer survivors. *J.Clin.Oncol.* 16 (2):495-500, 1998.
- S. Bhatia, M. E. Jenney, M. K. Bogue, T. H. Rockwood, J. H. Feusner, D. L. Friedman, L. L. Robison, and R. L. Kane. The Minneapolis-Manchester Quality of Life instrument: reliability and validity of the Adolescent Form. *J.Clin.Oncol.* 20 (24):4692-4698, 2002.
- P. Bonomi, K. Kim, D. Fairclough, D. Cella, J. Kugler, E. Rowinsky, M. Jiroutek, and D. Johnson. Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial. *J.Clin.Oncol.* 18 (3):623-631, 2000.
- A. S. Bradlyn and B. H. Pollock. Quality-of-life research in the Pediatric Oncology Group: 1991-1995. *J.Natl.Cancer Inst.Monogr* (20):49-53, 1996.
- C. P. Burns, S. Halabi, G. H. Clamon, V. Hars, B. A. Wagner, R. J. Hohl, E. Lester, J. J. Kirshner, V. Vinciguerra, and E. Paskett. Phase I clinical study of fish oil fatty acid capsules for patients with cancer cachexia: cancer and leukemia group B study 9473. *Clin.Cancer Res.* 5 (12):3942-3947, 1999.
- Matteson SE Morrow GR Roscoe JA Bushnow PW. patients with intractable chemotherapy induced nausea find acustimulation band helpful. Anonymous. Anonymous. *Proceedings American Society of Clinical Oncology* 21:263b, 2002.
- J. M. Childers, J. Chu, L. F. Voigt, P. Feigl, H. K. Tamimi, E. W. Franklin, D. S. Alberts, and F. L. Meyskens, Jr. Chemoprevention of cervical cancer with folic acid: a phase III Southwest Oncology Group Intergroup study. *Cancer Epidemiol.Biomarkers Prev.* 4 (2):155-159, 1995.
- S. F. Chong, M. E. Bretscher, J. A. Mailliard, L. K. Tschetter, D. W. Kimmel, A. K. Hatfield, and C. L. Loprinzi. Pilot study evaluating local anesthetics administered systemically for treatment of pain in patients with advanced cancer. *J.Pain Symptom.Manage.* 13 (2):112-117, 1997.
- D. Chu, K. Chansky, D. Alberts, R. Meyskens, G. Goodman, and S. Lippman. Adenoma recurrences after resection of colorectal carcinoma (CRC). *Oncology* 9(1):Suppl: S24 (#52), 2002.

- T. D. Chung, I. I. Park, L. Ignacio, R. Catchatourian, M. Kopnick, E. Davison, G. Conrad, A. M. Awan, D. Crawford, and S. Vijayakumar. Television and news print media are effective in recruiting potential participants in a prostate cancer chemoprevention trial. *Int.J.Cancer* 90 (5):302-304, 2000.
- C. Classen, S. Abramson, K. Angell, A. Atkinson, C. Desch, V. P. Vinciguerra, R. J. Rosenbluth, J. J. Kirshner, R. Hart, G. Morrow, and D. Spiegel. Effectiveness of a training program for enhancing therapists' understanding of the supportive-expressive treatment model for breast cancer groups. *J.Psychother.Pract.Res.* 6 (3):211-218, 1997.
- C. S. Cleeland, R. Gonin, A. K. Hatfield, J. H. Edmonson, R. H. Blum, J. A. Stewart, and K. J. Pandya. Pain and its treatment in outpatients with metastatic cancer. *N.Engl.J.Med.* 330 (9):592-596, 1994.
- M. A. Cobleigh, R. F. Berris, T. Bush, N. E. Davidson, N. J. Robert, J. A. Sparano, D. C. Tormey, and W. C. Wood. Estrogen replacement therapy in breast cancer survivors. A time for change. Breast Cancer Committees of the Eastern Cooperative Oncology Group. *JAMA* 272 (7):540-545, 1994.
- C. A. Coltman. The effect of finasteride on the prostate gland in men with elevated serum prostate-specific antigen level. *Br.J.Cancer* 81 (1):184-185, 1999.
- C. A. Coltman, Jr., I. M. Thompson, Jr., and P. Feigl. Prostate Cancer Prevention Trial (PCPT) update. *Eur.Urol.* 35 (5-6):544-547, 1999.
- J. Costantino. The impact of hormonal treatments on quality of life of patients with metastatic breast cancer. *Clin.Ther.* 24 Suppl C:C26-C42, 2002.
- J. P. Costantino, M. H. Gail, D. Pee, S. Anderson, C. K. Redmond, J. Benichou, and H. S. Wieand. Validation studies for models projecting the risk of invasive and total breast cancer incidence. *J.Natl.Cancer Inst.* 91 (18):1541-1548, 1999.
- J. P. Costantino and V. G. Vogel. Results and implications of the Royal Marsden and other tamoxifen chemoprevention trials: an alternative view. *Clin.Breast Cancer* 2 (1):41-46, 2001.
- J. P. Costantino. Benefit/risk assessment of SERM therapy: clinical trial versus clinical practice settings. *Ann.N.Y.Acad.Sci.* 949:280-285, 2001.
- C. A. Coyne, R. Xu, P. Raich, K. Plomer, M. Dignan, L. B. Wenzel, D. Fairclough, T. Habermann, L. Schnell, S. Quella, and D. Cella. Randomized, controlled trial of an easy-to-read informed consent statement for clinical trial participation: a study of the Eastern Cooperative Oncology Group. *J.Clin.Oncol.* 21 (5):836-842, 2003.
- M. Cushman, J. P. Costantino, R. P. Tracy, K. Song, L. Buckley, J. D. Roberts, and D. N. Krag. Tamoxifen and cardiac risk factors in healthy women: Suggestion of an anti-inflammatory effect. *Arterioscler.Thromb.Vasc.Biol.* 21 (2):255-261, 2001.
- M. Cushman, J. P. Costantino, E. G. Bovill, D. L. Wickerham, L. Buckley, J. D. Roberts, and D. N. Krag. Effect of tamoxifen on venous thrombosis risk factors in women without cancer: the Breast Cancer Prevention Trial. *Br.J.Haematol.* 120 (1):109-116, 2003.
- T. Davis, A. W. Miser, C. L. Loprinzi, J. S. Kaur, N. L. Burnham, A. M. Dose, and M. M. Ames. Comparative morphine pharmacokinetics following sublingual, intramuscular, and oral administration in patients with cancer. *Hosp.J.* 9 (1):85-90, 1993.
- N. A. Dawson, M. Conaway, S. Halabi, E. P. Winer, E. J. Small, D. Lake, and N. J. Vogelzang. A randomized study comparing standard versus moderately high dose megestrol acetate for patients with advanced prostate carcinoma: cancer and leukemia group B study 9181. *Cancer* 88 (4):825-834, 2000.

- R. Day, P. A. Ganz, J. P. Costantino, W. M. Cronin, D. L. Wickerham, and B. Fisher. Health-related quality of life and tamoxifen in breast cancer prevention: a report from the National Surgical Adjuvant Breast and Bowel Project P-1 Study. *J.Clin.Oncol.* 17 (9):2659-2669, 1999.
- R. Day. Quality of life and tamoxifen in a breast cancer prevention trial: a summary of findings from the NSABP P-1 study. National Surgical Adjuvant Breast and Bowel Project. *Ann.N.Y.Acad.Sci.* 949:143-150, 2001.
- R. Day, P. A. Ganz, and J. P. Costantino. Tamoxifen and depression: more evidence from the National Surgical Adjuvant Breast and Bowel Project's Breast Cancer Prevention (P-1) Randomized Study. *J.Natl.Cancer Inst.* 93 (21):1615-1623, 2001.
- A. S. Detsky, J. R. McLaughlin, J. P. Baker, N. Johnston, S. Whittaker, R. A. Mendelson, and K. N. Jeejeebhoy. What is subjective global assessment of nutritional status? *JPEN J.Parenter.Enteral Nutr.* 11 (1):8-13, 1987.
- J. J. Dignam, J. Bryant, H. S. Wieand, B. Fisher, and N. Wolmark. Early stopping of a clinical trial when there is evidence of no treatment benefit: protocol B-14 of the National Surgical Adjuvant Breast and Bowel Project. *Control Clin.Trials* 19 (6):575-588, 1998.
- J. J. Dignam. Differences in breast cancer prognosis among African-American and Caucasian women. *CA Cancer J.Clin.* 50 (1):50-64, 2000.
- B. K. Dunn, B. S. Kramer, and L. G. Ford. Phase III, large-scale chemoprevention trials. Approach to chemoprevention clinical trials and phase III clinical trial of tamoxifen as a chemopreventive for breast cancer--the US National Cancer Institute experience. *Hematol.Oncol.Clin.North Am.* 12 (5):1019-36, vii, 1998.
- M. A. Eisenberger, B. A. Blumenstein, E. D. Crawford, G. Miller, D. G. McLeod, P. J. Loehrer, G. Wilding, K. Sears, D. J. Culkun, I. M. Thompson, Jr., A. J. Bueschen, and B. A. Lowe. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. *N.Engl.J.Med.* 339 (15):1036-1042, 1998.
- S. C. Elliott, A. W. Miser, A. M. Dose, D. L. Betcher, J. R. O'Fallon, R. S. Ducos, N. R. Shah, T. S. Goh, C. M. Monzon, and L. Tschetter. Epidemiologic features of pain in pediatric cancer patients: a co-operative community-based study. North Central Cancer Treatment Group and Mayo Clinic). *Clin.J.Pain* 7 (4):263-268, 1991.
- N. Ellison, C. L. Loprinzi, J. Kugler, A. K. Hatfield, A. Miser, J. A. Sloan, D. B. Wender, K. M. Rowland, R. Molina, T. L. Cascino, A. M. Vukov, H. S. Dhaliwal, and C. Ghosh. Phase III placebo-controlled trial of capsaicin cream in the management of surgical neuropathic pain in cancer patients. *J.Clin.Oncol.* 15 (8):2974-2980, 1997.
- D. L. Fairclough, J. H. Fetting, D. Cella, W. Wonson, and C. M. Moinpour. Quality of life and quality adjusted survival for breast cancer patients receiving adjuvant therapy. Eastern Cooperative Oncology Group (ECOG). *Qual.Life Res.* 8 (8):723-731, 1999.
- P. Feigl, B. Blumenstein, I. Thompson, J. Crowley, M. Wolf, B. S. Kramer, C. A. Coltman, Jr., O. W. Brawley, and L. G. Ford. Design of the Prostate Cancer Prevention Trial (PCPT). *Control Clin.Trials* 16 (3):150-163, 1995.
- P. Fidler, C. L. Loprinzi, J. R. O'Fallon, J. M. Leitch, J. K. Lee, D. L. Hayes, P. Novotny, D. Clemens-Schutjer, J. Bartel, and J. C. Michalak. Prospective evaluation of a chamomile mouthwash for prevention of 5-FU- induced oral mucositis. *Cancer* 77 (3):522-525, 1996.
- G. Finck, D. L. Barton, C. L. Loprinzi, S. K. Quella, and J. A. Sloan. Definitions of hot flashes in breast cancer survivors. *J.Pain Symptom.Manage.* 16 (5):327-333, 1998.

- B. Fisher. A biological perspective of breast cancer: contributions of the National Surgical Adjuvant Breast and Bowel Project clinical trials. *CA Cancer J Clin.* 41 (2):97-111, 1991.
- B. Fisher and C. Redmond. New perspective on cancer of the contralateral breast: a marker for assessing tamoxifen as a preventive agent. *J Natl. Cancer Inst.* 83 (18):1278-1280, 1991.
- B. Fisher, J. Dignam, J. Bryant, A. DeCillis, D. L. Wickerham, N. Wolmark, J. Costantino, C. Redmond, E. R. Fisher, D. M. Bowman, L. Deschenes, N. V. Dimitrov, R. G. Margolese, A. Robidoux, H. Shibata, J. Terz, A. H. Paterson, M. I. Feldman, W. Farrar, J. Evans, and H. L. Lickley. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. *J Natl. Cancer Inst.* 88 (21):1529-1542, 1996.
- B. Fisher and J. Costantino. Highlights of the NSABP Breast Cancer Prevention Trial. *Cancer Control* 4 (1):78-86, 1997.
- B. Fisher, J. P. Costantino, D. L. Wickerham, C. K. Redmond, M. Kavanah, W. M. Cronin, V. Vogel, A. Robidoux, N. Dimitrov, J. Atkins, M. Daly, S. Wieand, E. Tan-Chiu, L. Ford, and N. Wolmark. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. *J. Natl. Cancer Inst.* 90 (18):1371-1388, 1998.
- B. Fisher. Highlights from recent National Surgical Adjuvant Breast and Bowel Project studies in the treatment and prevention of breast cancer. *CA Cancer J. Clin.* 49 (3):159-177, 1999.
- B. Fisher, J. Dignam, N. Wolmark, D. L. Wickerham, E. R. Fisher, E. Mamounas, R. Smith, M. Begovic, N. V. Dimitrov, R. G. Margolese, C. G. Kardinal, M. T. Kavanah, L. Fehrenbacher, and R. H. Oishi. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. *Lancet* 353 (9169):1993-2000, 1999.
- B. Fisher. From Halsted to prevention and beyond: advances in the management of breast cancer during the twentieth century. *Eur. J. Cancer* 35 (14):1963-1973, 1999.
- B. Fisher. National Surgical Adjuvant Breast and Bowel Project breast cancer prevention trial: a reflective commentary. *J. Clin. Oncol.* 17 (5):1632-1639, 1999.
- B. Fisher, J. Dignam, E. Tan-Chiu, S. Anderson, E. R. Fisher, J. L. Wittliff, and N. Wolmark. Prognosis and treatment of patients with breast tumors of one centimeter or less and negative axillary lymph nodes. *J. Natl. Cancer Inst.* 93 (2):112-120, 2001.
- B. Fisher, S. Land, E. Mamounas, J. Dignam, E. R. Fisher, and N. Wolmark. Prevention of invasive breast cancer in women with ductal carcinoma in situ: an update of the national surgical adjuvant breast and bowel project experience. *Semin. Oncol.* 28 (4):400-418, 2001.
- B. Fisher, J. Dignam, J. Bryant, and N. Wolmark. Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. *J. Natl. Cancer Inst.* 93 (9):684-690, 2001.
- B. Fisher, J. Bryant, J. J. Dignam, D. L. Wickerham, E. P. Mamounas, E. R. Fisher, R. G. Margolese, L. Nesbitt, S. Paik, T. M. Pisansky, and N. Wolmark. Tamoxifen, radiation therapy, or both for prevention of ipsilateral breast tumor recurrence after lumpectomy in women with invasive breast cancers of one centimeter or less. *J. Clin. Oncol.* 20 (20):4141-4149, 2002.
- J Fisher, C. Scott, C. Scarantino, F. G. Leveque, R White, M. Rotman, D. Hodson, R. Meredith, R. Foote, and A. S. Bradlyn. Phase III Quality of Life (QOL) Study: Reduction In Hyposalivation Does Not Improve QOL For Head and Neck (H&N) Cancer Patients Post Radiation Therapy (P-RT). RTOG 9709. *Proceedings from Am Soc Clin Oncol (ASCO)* 21:356a, 2003.

- Dressler C JE Herndon AB Kornblith Kerstine K Perry M Jablons D Sugarbaker D Hassler G Daniel T Fleishman S. Quality of life (QOL) advantage of sclerosis for malignant pleural effusion(MPE) via talc thoracoscopy over chest tube infusion of talc slurry: Cancer and Leukemia Group B Study 9334. *Proc ASCO* 21:1418, 2002.
- R. L. Foote, C. L. Loprinzi, A. R. Frank, J. R. O'Fallon, S. Gulavita, H. H. Tewfik, M. A. Ryan, J. M. Earle, and P. Novotny. Randomized trial of a chlorhexidine mouthwash for alleviation of radiation-induced mucositis. *J.Clin.Oncol.* 12 (12):2630-2633, 1994.
- M. H. Gail, J. P. Costantino, J. Bryant, R. Croyle, L. Freedman, K. Helzlsouer, and V. Vogel. Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. *J.Natl.Cancer Inst.* 91 (21):1829-1846, 1999.
- M. H. Gail and J. P. Costantino. Validating and improving models for projecting the absolute risk of breast cancer. *J.Natl.Cancer Inst.* 93 (5):334-335, 2001.
- P. A. Ganz, R. Day, J. E. Ware, Jr., C. Redmond, and B. Fisher. Base-line quality-of-life assessment in the National Surgical Adjuvant Breast and Bowel Project Breast Cancer Prevention Trial. *J.Natl.Cancer Inst.* 87 (18):1372-1382, 1995.
- P. A. Ganz, R. Day, and J. Costantino. Compliance with quality of life data collection in the National Surgical Adjuvant Breast and Bowel Project (NSABP) Breast Cancer Prevention Trial. *Stat.Med.* 17 (5-7):613-622, 1998.
- P. A. Ganz, S. Green, L. F. Hutchins, S. Martino, J. R. Granlow, K. S. Livingston, and K. S. Albain. Late cardiac effects of adjuvant CMF vs CAF in women with node negative breast cancer treated on SWOG 8897: initial results from SWOG 9342. Anonymous. *Breast Cancer Research and Treatment* 76 (Suppl 1):S157(#639), 2002.
- J. Gee, A. L. Sabichi, and H. B. Grossman. Chemoprevention of superficial bladder cancer. *Crit Rev.Oncol.Hematol.* 43 (3):277-286, 2002.
- R. M. Goldberg, C. L. Loprinzi, J. R. O'Fallon, M. H. Veeder, A. W. Miser, J. A. Mailliard, J. C. Michalak, A. M. Dose, K. M. Rowland, Jr., and N. L. Burnham. Transdermal clonidine for ameliorating tamoxifen-induced hot flashes. *J.Clin.Oncol.* 12 (1):155-158, 1994.
- R. M. Goldberg, C. G. Moertel, H. S. Wieand, J. E. Krook, A. J. Schutt, M. H. Veeder, J. A. Mailliard, and R. J. Dalton. A phase III evaluation of a somatostatin analogue (octreotide) in the treatment of patients with asymptomatic advanced colon carcinoma. North Central Cancer Treatment Group and the Mayo Clinic. *Cancer* 76 (6):961-966, 1995.
- W. Gordon, Jr., K. Siegmund, T. H. Stanisic, B. McKnight, I. T. Harris, P. R. Carroll, J. C. Paradelo, F. J. Meyers, R. A. Chapman, and F. L. Meyskens, Jr. A study of reproductive function in patients with seminoma treated with radiotherapy and orchidectomy: (SWOG-8711). Southwest Oncology Group. *Int.J.Radiat.Oncol.Biol.Phys.* 38 (1):83-94, 1997.
- M. B. Gorin, R. Day, J. P. Costantino, B. Fisher, C. K. Redmond, L. Wickerham, J. E. Gomolin, R. G. Margolese, M. K. Mathen, D. M. Bowman, D. I. Kaufman, N. V. Dimitrov, L. J. Singerman, R. Bornstein, N. Wolmark, and D. Kaufmann. Long-term tamoxifen citrate use and potential ocular toxicity. *Am.J.Ophthalmol.* 125 (4):493-501, 1998.
- B. S. Gostout, L. C. Hartmann, V. J. Suman, N. E. Fay, J. A. Jefferies, R. F. Morton, T. A. Gaffey, G. H. Farr, Jr., L. K. Tschetter, S. Abu-Ghazaleh, M. M. Gallenberg, and A. K. Hatfield. A randomized trial of interferon-alpha in cervical dysplasia. *Int.J.Gynaecol.Obstet.* 74 (2):207-210, 2001.
- K. E. Greco and L. Kulawiak. Prostate cancer prevention: risk reduction through life-style, diet, and chemoprevention. *Oncol.Nurs.Forum* 21 (9):1504-1511, 1994.

- D. B. Greenberg, A. B. Kornblith, J. E. Herndon, E. Zuckerman, C. A. Schiffer, R. B. Weiss, R. J. Mayer, S. M. Wolchok, and J. C. Holland. Quality of life for adult leukemia survivors treated on clinical trials of Cancer and Leukemia Group B during the period 1971-1988: predictors for later psychologic distress. *Cancer* 80 (10):1936-1944, 1997.
- S. M. Grunberg, J. E. Herndon, K. Zhang, A. Kessinger, D. Christian, and J. Weeks. Characterization of patient utility for chemotherapy induced nausea and vomiting (CINV). *Support Care Cancer* 10:624-629, 2002.
- S. M. Grunberg, A. Srivastava, K. J. Grunberg, and J. Weeks. Intensity of chemotherapy-induced emesis and overall survival as determinants of a global utility score. *Support Care Cancer* 10 (8):624-629, 2002.
- T. Guttuso, Jr., J. Roscoe, and J. Griggs. Effect of gabapentin on nausea induced by chemotherapy in patients with breast cancer. *Lancet* 361 (9370):1703-1705, 2003.
- E. A. Hahn, K. A. Webster, D. Cella, and D. L. Fairclough. Missing data in quality of life research in Eastern Cooperative Oncology Group (ECOG) clinical trials: problems and solutions. *Stat.Med.* 17 (5-7):547-559, 1998.
- J. E. Hammack, J. A. Mailliard, C. L. Loprinzi, R. M. Rospond, J. R. O'Fallon, M. B. Wilwerding, N. F. Reuter, J. C. Michalak, P. Fidler, and A. W. Miser. Transdermal fentanyl in the management of cancer pain in ambulatory patients: an open-label pilot study. *J.Pain Symptom.Manage.* 12 (4):234-240, 1996.
- J. E. Hammack, J. C. Michalak, C. L. Loprinzi, J. A. Sloan, P. J. Novotny, G. S. Soori, M. T. Tirona, K. M. Rowland, Jr., P. J. Stella, and J. A. Johnson. Phase III evaluation of nortriptyline for alleviation of symptoms of cis-platinum-induced peripheral neuropathy 1. *Pain* 98 (1-2):195-203, 2002.
- K. A. Hayden, C. M. Moinpour, B. Metch, P. Feigl, R. M. O'Bryan, S. Green, and C. K. Osborne. Pitfalls in quality-of-life assessment: lessons from a Southwest Oncology Group breast cancer clinical trial. *Oncol.Nurs.Forum* 20 (9):1415-1419, 1993.
- J. E. Herndon, S. Fleishman, A. B. Kornblith, M. Kosty, M. R. Green, and J. Holland. Is quality of life predictive of the survival of patients with advanced nonsmall cell lung carcinoma? *Cancer* 85 (2):333-340, 1999.
- J. T. Hickok, G. R. Morrow, S. McDonald, and A. J. Bellg. Frequency and correlates of fatigue in lung cancer patients receiving radiation therapy: implications for management. *J.Pain Symptom.Manage.* 11 (6):370-377, 1996.
- J. T. Hickok, J. A. Roscoe, G. R. Morrow, R. M. Stern, B. Yang, P. J. Flynn, H. E. Hynes, J. J. Kirshner, and R. J. Rosenbluth. Use of 5-HT3 receptor antagonists to prevent nausea and emesis caused by chemotherapy for patients with breast carcinoma in community practice settings. *Cancer* 86 (1):64-71, 1999.
- J. T. Hickok, J. A. Roscoe, G. R. Morrow, D. K. King, J. N. Atkins, and T. R. Fitch. Nausea and emesis remain significant problems of chemotherapy despite prophylaxis with 5-hydroxytryptamine-3 antiemetics: a University of Rochester James P. Wilmot Cancer Center Community Clinical Oncology Program Study of 360 cancer patients treated in the community. *Cancer* 97 (11):2880-2886, 2003.
- Roscoe JA Haller M Ling M Brasacchio R Holmstedt DJ and Morrow GR. An assessment of fatigue, pain and nausea in patients receiving radiation treatments. Anonymous. Anonymous. *Supportive Care In Cancer* :366, 2002.

- A. Hoque, D. Albanes, S. M. Lippman, M. R. Spitz, P. R. Taylor, E. A. Klein, I. M. Thompson, P. Goodman, J. L. Stanford, J. J. Crowley, C. A. Coltman, and R. M. Santella. Molecular epidemiologic studies within the Selenium and Vitamin E Cancer Prevention Trial (SELECT). *Cancer Causes Control* 12 (7):627-633, 2001.
- R. D. Hurt, J. E. Krook, I. T. Croghan, C. L. Loprinzi, J. A. Sloan, P. J. Novotny, C. G. Kardinal, J. A. Knost, M. T. Tirona, F. Addo, R. F. Morton, J. C. Michalak, P. L. Schaefer, P. A. Porter, and P. J. Stella. Nicotine patch therapy based on smoking rate followed by bupropion for prevention of relapse to smoking. *J.Clin.Oncol.* 21 (5):914-920, 2003.
- J. N. Ingle, J. E. Krook, D. J. Schaid, L. K. Everson, J. A. Mailliard, H. J. Long, and G. W. McCormack. Evaluation of trilostane plus hydrocortisone in women with metastatic breast cancer and prior hormonal therapy exposure. *Am.J.Clin.Oncol.* 13 (2):93-97, 1990.
- A. Jatoi, H. E. Windschitl, C. L. Loprinzi, J. A. Sloan, S. R. Dakhil, J. A. Mailliard, S. Pundaleeka, C. G. Kardinal, T. R. Fitch, J. E. Krook, P. J. Novotny, and B. Christensen. Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: a north central cancer treatment group study. *J.Clin.Oncol.* 20 (2):567-573, 2002.
- A. Jatoi, J. Yamashita, J. A. Sloan, P. J. Novotny, H. E. Windschitl, and C. L. Loprinzi. Does megestrol acetate down-regulate interleukin-6 in patients with cancer-associated anorexia and weight loss? A North Central Cancer Treatment Group investigation. *Support.Care Cancer* 10 (1):71-75, 2002.
- D. J. Johnson, C. B. Scott, J. E. Marks, T. E. Seay, J. N. Atkins, L. B. Berk, R. T. Meoz, and J. A. Wheeler. Assessment of quality of life and oral function of patients participating in a phase II study of radioprotection of oral and pharyngeal mucosa by the prostaglandin E(1) analog misoprostol (RTOG 96- 07). *Int.J.Radiat.Oncol.Biol.Phys.* 54 (5):1455-1459, 2002.
- V. Craig Jordan, Susan Gapstur, and Monica Morrow. Selective Estrogen Receptor Modulation and Reduction in Risk of Breast Cancer, Osteoporosis, and Coronary Heart Disease. *JNCI Cancer Spectrum* 93 (19):1449-1457, 2001.
- C. G. Kardinal, C. L. Loprinzi, D. J. Schaid, A. C. Hass, A. M. Dose, L. M. Athmann, J. A. Mailliard, G. W. McCormack, J. B. Gerstner, and M. F. Schray. A controlled trial of cyproheptadine in cancer patients with anorexia and/or cachexia. *Cancer* 65 (12):2657-2662, 1990.
- G. Kiebert, S. Wait, J. Bernhard, A. Bezjak, D. Cella, R. Day, J. Houghton, C. Moinpour, C. Scott, and R. Stephens. Practice and policy of measuring quality of life and health economics in cancer clinical trials: a survey among co-operative trial groups. *Qual.Life Res.* 9 (10):1073-1080, 2000.
- Roscoe JA Morrow GR Kim Y. The predictors of development of fatigue and depression in cancer patients undergoing chemotherapy. 25:S119, 2003.
- Y. Kim, Roscoe JA, and Morrow GR. The effects of information and negative affect on severity of side effects from radiation therapy for prostate cancer. *Supportive Care in Cancer* 10 5:416-421, 2002.
- M. C. King, S. Wieand, K. Hale, M. Lee, T. Walsh, K. Owens, J. Tait, L. Ford, B. K. Dunn, J. Costantino, L. Wickerham, N. Wolmark, and B. Fisher. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. *JAMA* 286 (18):2251-2256, 2001.
- T. M. King, Z. Trizna, X. Wu, C. I. Amos, R. H. Fueger, J. J. Fueger, H. A. Fritsche, T. C. Hsu, R. Winn, and M. R. Spitz. A clinical trial to evaluate the effect of vitamin C supplementation on in vitro mutagen sensitivity. The University of Texas M. D. Anderson Clinical Community Oncology Program Network. *Cancer Epidemiol.Biomarkers Prev.* 6 (7):537-542, 1997.

- E. A. Klein, I. M. Thompson, S. M. Lippman, P. J. Goodman, D. Albanes, P. R. Taylor, and C. Coltman. SELECT: the next prostate cancer prevention trial. Selenium and Vitamin E Cancer Prevention Trial. *J.Urol.* 166 (4):1311-1315, 2001.
- E. A. Klein. The role of PC-SPEs, selenium and vitamin E in prostate cancer. Anonymous. Anonymous. *Oncology* 16(3):296-300, 2002.
- B. Kleinman, A. Darke, and J. A. Hartline. The challenges and benefits of a web based trial. *Controlled Clinical Trials* 23(2S):91S-92S (#P 62), 2002.
- Butler LD Classen C Giese-Davis J Morrow GR Westendrop J Banerjee T Spiegel D Koopman C. Traumatic stress symptoms among women with recently diagnosed primary breast cancer. *Journal of Traumatic Stress* 15 4:277-287, 2002.
- A. B. Kornblith, J. E. Herndon, E. Zuckerman, D. F. Cella, E. Cherin, S. Wolchok, R. B. Weiss, L. F. Diehl, E. Henderson, M. R. Cooper, C. Schiffer, G. P. Canellos, R. J. Mayer, R. T. Silver, A. Schilling, B. A. Peterson, D. Greenberg, and J. C. Holland. Comparison of psychosocial adaptation of advanced stage Hodgkin's disease and acute leukemia survivors. *Cancer and Leukemia Group B. Ann.Oncol.* 9 (3):297-306, 1998.
- A. B. Kornblith, J. E. Herndon, E. Zuckerman, C. M. Viscoli, R. I. Horwitz, M. R. Cooper, L. Harris, K. H. Tkaczuk, M. C. Perry, D. Budman, L. C. Norton, and J. Holland. Social support as a buffer to the psychological impact of stressful life events in women with breast cancer. *Cancer* 91 (2):443-454, 2001.
- A. B. Kornblith, M. Kemeny, B. L. Peterson, J. Wheeler, J. Crawford, N. Bartlett, G. Fleming, S. Graziano, H. Muss, and H. J. Cohen. Survey of oncologists' perceptions of barriers to accrual of older patients with breast carcinoma to clinical trials. *Cancer*: 989-996, 2002.
- J. P. Krischer, S. W. Roush, M. W. Cox, and B. H. Pollock. Using a population-based registry to identify patterns of care in childhood cancer in Florida. *Cancer* 71 (10 Suppl):3331-3336, 1993.
- S. S. Lentz, M. F. Brady, F. J. Major, G. C. Reid, and J. T. Soper. High-dose megestrol acetate in advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study. *J.Clin.Oncol.* 14 (2):357-361, 1996.
- S. M. Lippman, J. J. Lee, D. D. Karp, E. E. Vokes, S. E. Benner, G. E. Goodman, F. R. Khuri, R. Marks, R. J. Winn, W. Fry, S. L. Graziano, D. R. Gandara, G. Okawara, C. L. Woodhouse, B. Williams, C. Perez, H. W. Kim, R. Lotan, J. A. Roth, and W. K. Hong. Randomized phase III intergroup trial of isotretinoin to prevent second primary tumors in stage I non-small-cell lung cancer. *J.Natl.Cancer Inst.* 93 (8):605-618, 2001.
- C. L. Loprinzi, S. G. Cianflone, A. M. Dose, P. S. Etzell, N. L. Burnham, T. M. Therneau, L. Hagen, D. K. Gainey, M. Cross, L. M. Athmann, and . A controlled evaluation of an allopurinol mouthwash as prophylaxis against 5-fluorouracil-induced stomatitis. *Cancer* 65 (8):1879-1882, 1990.
- C. L. Loprinzi, N. M. Ellison, D. J. Schaid, J. E. Krook, L. M. Athmann, A. M. Dose, J. A. Mailliard, P. S. Johnson, L. P. Ebbert, and L. H. Geeraerts. Controlled trial of megestrol acetate for the treatment of cancer anorexia and cachexia. *J.Natl.Cancer Inst.* 82 (13):1127-1132, 1990.
- C. L. Loprinzi, R. M. Goldberg, J. Q. Su, J. A. Mailliard, S. A. Kuross, A. W. Maksymiuk, J. W. Kugler, J. R. Jett, C. Ghosh, D. M. Pfeifle, and . Placebo-controlled trial of hydrazine sulfate in patients with newly diagnosed non-small-cell lung cancer. *J.Clin.Oncol.* 12 (6):1126-1129, 1994.
- C. L. Loprinzi, J. C. Michalak, S. K. Quella, J. R. O'Fallon, A. K. Hatfield, R. A. Nelimark, A. M. Dose, T. Fischer, C. Johnson, N. E. Klatt, and . Megestrol acetate for the prevention of hot flashes. *N.Engl.J.Med.* 331 (6):347-352, 1994.

- C. L. Loprinzi, S. A. Kuross, J. R. O'Fallon, D. H. Gesme, Jr., J. B. Gerstner, R. M. Rospond, C. D. Cobau, and R. M. Goldberg. Randomized placebo-controlled evaluation of hydrazine sulfate in patients with advanced colorectal cancer. *J.Clin.Oncol.* 12 (6):1121-1125, 1994.
- C. L. Loprinzi, J. A. Laurie, H. S. Wieand, J. E. Krook, P. J. Novotny, J. W. Kugler, J. Bartel, M. Law, M. Bateman, N. E. Klatt, and . Prospective evaluation of prognostic variables from patient-completed questionnaires. North Central Cancer Treatment Group. *J.Clin.Oncol.* 12 (3):601-607, 1994.
- C. L. Loprinzi, D. B. Wender, M. H. Veeder, J. R. O'Fallon, N. L. Vaught, A. M. Dose, C. Ghosh, J. Bartel, and J. M. Leitch. Inhibition of 5-fluorouracil-induced ocular irritation by ocular ice packs. *Cancer* 74 (3):945-948, 1994.
- C. L. Loprinzi, A. M. Bernath, D. J. Schaid, J. A. Malliard, L. M. Athmann, J. C. Michalak, L. K. Tschetter, A. K. Hatfield, and R. F. Morton. Phase III evaluation of 4 doses of megestrol acetate as therapy for patients with cancer anorexia and/or cachexia. *Oncology* 51 Suppl 1:2-7, 1994.
- C. L. Loprinzi, R. M. Goldberg, J. R. O'Fallon, S. K. Quella, A. W. Miser, L. A. Mynderse, L. D. Brown, L. K. Tschetter, M. B. Wilwerding, M. Dose, and . Transdermal clonidine for ameliorating post-orchietomy hot flashes. *J.Urol.* 151 (3):634-636, 1994.
- C. L. Loprinzi, R. L. Foote, and J. Michalak. Alleviation of cytotoxic therapy-induced normal tissue damage. *Semin.Oncol.* 22 (2 Suppl 3):95-97, 1995.
- C. L. Loprinzi, L. M. Athmann, C. G. Kardinal, J. R. O'Fallon, J. A. See, B. K. Bruce, A. M. Dose, A. W. Miser, P. S. Kern, L. K. Tschetter, and S. Rayson. Randomized trial of dietician counseling to try to prevent weight gain associated with breast cancer adjuvant chemotherapy. *Oncology* 53 (3):228-232, 1996.
- C. L. Loprinzi, E. M. Messing, J. R. O'Fallon, M. A. Poon, R. R. Love, S. K. Quella, D. L. Trump, R. F. Morton, and P. Novotny. Toxicity evaluation of difluoromethylornithine: doses for chemoprevention trials. *Cancer Epidemiol.Biomarkers Prev.* 5 (5):371-374, 1996.
- C. L. Loprinzi, C. Ghosh, J. Camoriano, J. Sloan, P. D. Steen, J. C. Michalak, P. L. Schaefer, P. J. Novotny, J. B. Gerstner, D. F. White, A. K. Hatfield, and S. K. Quella. Phase III controlled evaluation of sucralfate to alleviate stomatitis in patients receiving fluorouracil-based chemotherapy. *J.Clin.Oncol.* 15 (3):1235-1238, 1997.
- C. L. Loprinzi, S. Abu-Ghazaleh, J. A. Sloan, C. vanHaelst-Pisani, A. M. Hammer, K. M. Rowland, Jr., M. Law, H. E. Windschitl, J. S. Kaur, and N. Ellison. Phase III randomized double-blind study to evaluate the efficacy of a polycarbophil-based vaginal moisturizer in women with breast cancer. *J.Clin.Oncol.* 15 (3):969-973, 1997.
- D. J. Mahood, A. M. Dose, C. L. Loprinzi, M. H. Veeder, L. M. Athmann, T. M. Therneau, J. M. Sorensen, D. K. Gainey, J. A. Mailliard, N. L. Gusa, and . Inhibition of fluorouracil-induced stomatitis by oral cryotherapy. *J.Clin.Oncol.* 9 (3):449-452, 1991.
- M. Markman, K. A. Iseminger, K. D. Hatch, W. T. Creasman, W. Barnes, and B. Dubeshter. Tamoxifen in platinum-refractory ovarian cancer: a Gynecologic Oncology Group Ancillary Report. *Gynecol.Oncol.* 62 (1):4-6, 1996.
- W. L. McGinnis, C. L. Loprinzi, S. J. Buskirk, J. A. Sloan, R. G. Drummond, A. R. Frank, T. G. Shanahan, S. P. Kahanic, R. L. Moore, S. E. Schild, and S. L. Humphrey. Placebo-controlled trial of sucralfate for inhibiting radiation-induced esophagitis. *J.Clin.Oncol.* 15 (3):1239-1243, 1997.

- F. L. Meyskens, Jr., P. Y. Liu, R. J. Tuthill, V. K. Sondak, W. S. Fletcher, W. R. Jewell, W. Samlowski, S. P. Balcerzak, D. J. Rector, R. D. Noyes, and . Randomized trial of vitamin A versus observation as adjuvant therapy in high-risk primary malignant melanoma: a Southwest Oncology Group study. *J.Clin.Oncol.* 12 (10):2060-2065, 1994.
- A. W. Miser, T. S. Goh, A. M. Dose, J. R. O'Fallon, R. D. Niedringhaus, D. L. Betcher, P. Simmons, D. J. MacKellar, M. Arnold, and C. L. Loprinzi. Trial of a topically administered local anesthetic (EMLA cream) for pain relief during central venous port accesses in children with cancer. *J.Pain Symptom.Manage.* 9 (4):259-264, 1994.
- C. M. Moinpour, Triplett J. Sawyers, B. McKnight, L. C. Lovato, C. Upchurch, C. G. Leichman, F. M. Muggia, L. Tanaka, W. A. James, M. Lennard, and F. L. Meyskens, Jr. Challenges posed by non-random missing quality of life data in an advanced-stage colorectal cancer clinical trial. *Psychooncology.* 9 (4):340-354, 2000.
- C. M. Moinpour, J. O. Atkinson, S. M. Thomas, S. M. Underwood, C. Harvey, J. Parzuchowski, L. C. Lovato, A. M. Ryan, M. S. Hill, E. Deantoni, E. R. Gritz, I. M. Thompson, Jr., and C. A. Coltman, Jr. Minority recruitment in the prostate cancer prevention trial. *Ann.Epidemiol.* 10 (8 Suppl) :S85-S91, 2000.
- C. M. Moinpour, B. Lyons, S. P. Schmidt, K. Chansky, and R. A. Patchell. Substituting proxy ratings for patient ratings in cancer clinical trials: an analysis based on a Southwest Oncology Group trial in patients with brain metastases. *Qual.Life Res.* 9 (2):219-231, 2000.
- C. M. Moinpour, L. C. Lovato, I. M. Thompson, Jr., J. E. Ware, Jr., P. A. Ganz, D. L. Patrick, S. A. Shumaker, G. W. Donaldson, A. Ryan, and C. A. Coltman, Jr. Profile of men randomized to the prostate cancer prevention trial: baseline health-related quality of life, urinary and sexual functioning, and health behaviors. *J.Clin.Oncol.* 18 (9):1942-1953, 2000.
- C. M. Moinpour, B. Lyons, LC Gevstad, J Lovato, J. Crowley, ZM Czaplicki, PA Buckner, P. A. Ganz, K Kelly, and D. R. Gandara. Quality of life in advanced non small cell lung cancer: results of a Southwest Oncology group randomized trial. *Quality of Life Research* 11:115-126, 2002.
- C. M. Moinpour, B. Lyons, S. McCoy, G. L. Winakur, P. Y. Liu, and M. L. Rothenberg. HRQL outcomes in phase II trial for patients with recurrent ovarian cancer: was palliation achieved? *Quality of Life Research* 11(7):660 (#157), 2002.
- Andrews PL Morrow GR and JT Roscoe JA Matteson S Hickok. Fatigue associated with cancer and its treatment. *Supportive Care in Cancer* 10 5:389-398, 2002.
- G. R. Morrow and S. N. Rosenthal. Models, mechanisms and management of anticipatory nausea and emesis. *Oncology* 53 Suppl 1:4-7, 1996.
- G. R. Morrow, J. A. Roscoe, H. E. Hynes, P. J. Flynn, H. I. Pierce, and T. Burish. Progress in reducing anticipatory nausea and vomiting: a study of community practice. *Support.Care Cancer* 6 (1):46-50, 1998.
- G. R. Morrow, J. A. Roscoe, J. T. Hickok, P. R. Andrews, and S. Matteson. Nausea and emesis: evidence for a biobehavioral perspective. *Support.Care Cancer* 10 (2):96-105, 2002.
- M. L. Neuhouser, A. R. Kristal, D. McLerran, R. E. Patterson, and J. Atkinson. Validity of short food frequency questionnaires used in cancer chemoprevention trials: results from the Prostate Cancer Prevention Trial. *Cancer Epidemiol.Biomarkers Prev.* 8 (8):721-725, 1999.

- M. L. Neuhouser, A. R. Kristal, R. E. Patterson, P. J. Goodman, and I. M. Thompson. Dietary supplement use in the Prostate Cancer Prevention Trial: implications for prevention trials. *Nutr.Cancer* 39 (1):12-18, 2001.
- M. M. Oken, C. Pomeroy, D. Weisdorf, and J. M. Bennett. Prophylactic antibiotics for the prevention of early infection in multiple myeloma. *Am.J.Med.* 100 (6):624-628, 1996.
- S. H. Okuno, R. L. Foote, C. L. Loprinzi, S. Gulavita, J. A. Sloan, J. Earle, P. J. Novotny, M. Burk, and A. R. Frank. A randomized trial of a nonabsorbable antibiotic lozenge given to alleviate radiation-induced mucositis. *Cancer* 79 (11):2193-2199, 1997.
- K. J. Pandya, R. F. Raubertas, P. J. Flynn, H. E. Hynes, R. J. Rosenbluth, J. J. Kirshner, H. I. Pierce, V. Dragalin, and G. R. Morrow. Oral clonidine in postmenopausal patients with breast cancer experiencing tamoxifen-induced hot flashes: a University of Rochester Cancer Center Community Clinical Oncology Program study. *Ann.Intern.Med.* 132 (10):788-793, 2000.
- E. D. Paskett, M. R. Cooper, C. R. DeGraffinreid, C. L. Spurr, and T. A. Dolecek. Community Clinical Oncology Program as a recruitment vehicle for cancer control research. The Southeast Cancer Control Consortium experience. *N.C.Med.J.* 56 (6):283-286, 1995.
- E. D. Paskett, C. DeGraffinreid, C. M. Tatum, and S. E. Margitic. The recruitment of African-Americans to cancer prevention and control studies. *Prev.Med.* 25 (5):547-553, 1996.
- L. Psillidis, J. Flach, and R. M. Padberg. Participants strengthen clinical trial research: the vital role of participant advisors in the Breast Cancer Prevention Trial. *J Womens Health* 6 (2):227-232, 1997.
- S. Quella, C. L. Loprinzi, and A. M. Dose. A qualitative approach to defining "hot flashes" in men. *Urol.Nurs.* 14 (4):155-158, 1994.
- Morrow GR Ranson SL. Synchronizing multicenter trials with the internet. *Supportive Care In Cancer* 10(4):351-382, 2002.
- M. J. Ratain, G. Rosner, S. L. Allen, M. Costanza, D. A. Van Echo, I. C. Henderson, and R. L. Schilsky. Population pharmacodynamic study of amonafide: a Cancer and Leukemia Group B study. *J.Clin.Oncol.* 13 (3):741-747, 1995.
- S. E. Reis, J. P. Costantino, D. L. Wickerham, E. Tan-Chiu, J. Wang, and M. Kavanah. Cardiovascular effects of tamoxifen in women with and without heart disease: breast cancer prevention trial. National Surgical Adjuvant Breast and Bowel Project Breast Cancer Prevention Trial Investigators. *J.Natl.Cancer Inst.* 93 (1):16-21, 2001.
- M. Roach, III, C. Cirrincione, D. Budman, D. Hayes, D. Berry, J. Younger, R. Hart, and I. C. Henderson. Race and survival from breast cancer: based on Cancer and Leukemia Group B trial 8541. *Cancer.J.Sci.Am.* 3 (2):107-112, 1997.
- L. K. Rocke, C. L. Loprinzi, J. K. Lee, S. J. Kunselman, R. K. Iverson, G. Finck, D. Lifsey, K. C. Glaw, B. A. Stevens, A. K. Hatfield, and . A randomized clinical trial of two different durations of oral cryotherapy for prevention of 5-fluorouracil-related stomatitis. *Cancer* 72 (7):2234-2238, 1993.
- Roscoe JA and Hickok JT Pierce HI Flynn PJ Dakhil SR Morrow GR. Patient characteristics associated with the development of chemotherapy induced nausea. *Supportive Care in Cancer*, 14th International Symposium 10 4:363, 2002.

- Morrow GR Roscoe JA. Multicenter URCC CCOP study finds acupressure wrist bands helpful for control of nausea following chemotherapy. *Supportive Care In Cancer* 10(4):364, 2002.
- Morrow GR Hickok JT Bushnow P Matteson S Rakita D Andrews PL Roscoe JA. Temporal interrelationships among fatigue, circadian rhythm and depression in breast cancer patients undergoing chemoherapy treatment. *Supportive Care In Cancer* 4(10):329-336, 2002.
- J. A. Roscoe, G. R. Morrow, J. T. Hickok, and R. M. Stern. Nausea and vomiting remain a significant clinical problem: trends over time in controlling chemotherapy-induced nausea and vomiting in 1413 patients treated in community clinical practices. *J.Pain Symptom.Manage.* 20 (2): 113-121, 2000.
- J. A. Roscoe and S. E. Matteson. Acupressure and acustimulation bands for control of nausea: a brief review. *Am.J.Obstet.Gynecol.* 185 (5 Suppl Understanding):S244-S247, 2002.
- J. A. Roscoe, G. R. Morrow, P. Bushunow, L. Tian, and S. Matteson. Acustimulation wristbands for the relief chemotherapy-induced nausea. *Altern.Ther.Health Med.* 8 (4):56-63, 2002.
- S. W. Roush, J. P. Krischer, M. W. Cox, and B. H. Pollock. Socioeconomic and demographic factors that predict where children receive cancer care in Florida. *J.Clin.Epidemiol.* 46 (6):535-544, 1993.
- R. S. Sandler, S. Halabi, E. B. Kaplan, J. A. Baron, E. Paskett, and N. J. Petrelli. Use of vitamins, minerals, and nutritional supplements by participants in a chemoprevention trial. *Cancer* 91 (5):1040-1045, 2001.
- R. S. Sandler, S. Halabi, J. A. Baron, S. Budinger, E. Paskett, R. Keresztes, N. Petrelli, J. M. Pipas, D. D. Karp, C. L. Loprinzi, G. Steinbach, and R. Schilsky. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. *N.Engl.J.Med.* 348 (10):883-890, 2003.
- A. Schilling, M. R. Conaway, P. J. Wingate, J. N. Atkins, I. M. Berkowitz, G. H. Clamon, S. M. DiFino, and V. Vinciguerra. Recruiting cancer patients to participate in motivating their relatives to quit smoking. A cancer control study of the Cancer and Leukemia Group B (CALGB 9072). *Cancer* 79 (1):152-160, 1997.
- R. A. Schnoll, B. Zhang, M. Rue, J. E. Krook, W. T. Spears, A. C. Marcus, and P. F. Engstrom. Brief physician-initiated quit-smoking strategies for clinical oncology settings: a trial coordinated by the Eastern Cooperative Oncology Group. *J.Clin.Oncol.* 21 (2):355-365, 2003.
- Rosdhal R Culbreth M et al Shaw E. Phase II Study of Donepezil (Aricept) in Cognitively Impaired Brain Tumor Patients. Anonymous. Anonymous. *Neuro-Oncology* 4(4):350, 2002.
- D. Spiegel, J. R. Bloom, H. C. Kraemer, and E. Gotthel. Effect of psychosocial treatment on survival of patients with metastatic breast cancer. *Lancet* 2 (8668):888-891, 1989.
- D. Spiegel, G. R. Morrow, C. Classen, R. Raubertas, P. B. Stott, N. Mudaliar, H. I. Pierce, P. J. Flynn, L. Heard, and G. Riggs. Group psychotherapy for recently diagnosed breast cancer patients: a multicenter feasibility study. *Psychooncology.* 8 (6):482-493, 1999.
- C. K. Stein, T. W. Glover, J. L. Palmer, and B. S. Glisson. Direct correlation between FRA3B expression and cigarette smoking. *Genes Chromosomes. Cancer* 34 (3):333-340, 2002.
- C. J. Strickland, P. Feigl, C. Upchurch, D. K. King, H. I. Pierce, P. K. Grevstad, J. D. Bearden, III, M. Dawson, W. C. Loewen, and F. L. Meyskens, Jr. Improving breast self-examination compliance: a Southwest Oncology Group randomized trial of three interventions. *Prev.Med.* 26 (3):320-332, 1997.
- E. Tan-Chiu, J. Wang, J. P. Costantino, S. Paik, C. Butch, D. L. Wickerham, B. Fisher, and N. Wolmark. Effects of tamoxifen on benign breast disease in women at high risk for breast cancer. *J.Natl.Cancer Inst.* 95 (4):302-307, 2003.

- M. L. Tao, M. D. Guo, R. Weiss, J. Byrne, J. L. Mills, L. L. Robison, and L. K. Zeltzer. Smoking in adult survivors of childhood acute lymphoblastic leukemia. *J.Natl.Cancer Inst.* 90 (3):219-225, 1998.
- C. W. Taylor, S. Green, W. S. Dalton, S. Martino, D. Rector, J. N. Ingle, N. J. Robert, G. T. Budd, J. C. Paradelo, R. B. Natale, J. D. Bearden, J. A. Mailliard, and C. K. Osborne. Multicenter randomized clinical trial of goserelin versus surgical ovariectomy in premenopausal patients with receptor-positive metastatic breast cancer: an intergroup study. *J.Clin.Oncol.* 16 (3):994-999, 1998.
- K. M. Taylor, M. L. Feldstein, R. T. Skeel, K. J. Pandya, P. Ng, and P. P. Carbone. Fundamental dilemmas of the randomized clinical trial process: results of a survey of the 1,737 Eastern Cooperative Oncology Group investigators. *J.Clin.Oncol.* 12 (9):1796-1805, 1994.
- I. Thompson, P. Feigl, and C. Coltman. Chemoprevention of prostate cancer with finasteride. *Important Adv.Oncol.* :57-76, 1995.
- I. M. Thompson, C. A. Coltman, O. W. Brawley, and A. Ryan. Chemoprevention of prostate cancer. *Semin.Urol.* 13 (2):122-129, 1995.
- I. M. Thompson and C. A. Coltman. Screening for prostate cancer: opportunities for prevention. *Semin.Urol.Oncol.* 14 (2 Suppl 2):4-10, 1996.
- I. M. Thompson, C. A. Coltman, Jr., and J. Crowley. Chemoprevention of prostate cancer: the Prostate Cancer Prevention Trial. *Prostate* 33 (3):217-221, 1997.
- I. M. Thompson, P. J. Goodman, C. Tangen, M. S. Lucia, G. Miller, L. Ford, M. Lieber, R. D. Cespedes, J. Atkins, S. Lippman, S. Carlin, A. Ryan, C. Szczepanek, J. Crowley, and C. Coltman. The Influence of Finasteride on the Development of Prostate Cancer. Anonymous. Anonymous. *N Engl J Med* 349(3):213-222, 2003.
- I. M. Thompson, Jr., M. Kouril, E. A. Klein, C. A. Coltman, A. Ryan, and P. Goodman. The Prostate Cancer Prevention Trial: Current status and lessons learned. *Urology* 57 (4 Suppl 1):230-234, 2001.
- V. G. Vogel. Breast cancer prevention: a review of current evidence. *CA Cancer J.Clin.* 50 (3):156-170, 2000.
- V. G. Vogel, J. P. Costantino, D. L. Wickerham, W. M. Cronin, and N. Wolmark. The study of tamoxifen and raloxifene: preliminary enrollment data from a randomized breast cancer risk reduction trial. *Clin.Breast Cancer* 3 (2):153-159, 2002.
- V. G. Vogel, J. P. Costantino, D. L. Wickerham, and W. M. Cronin. National surgical adjuvant breast and bowel project update: prevention trials and endocrine therapy of ductal carcinoma in situ. *Clin.Cancer Res.* 9 (1 Pt 2):495S-501S, 2003.
- J. H. Von Roenn, C. S. Cleeland, R. Gonin, A. K. Hatfield, and K. J. Pandya. Physician attitudes and practice in cancer pain management. A survey from the Eastern Cooperative Oncology Group. *Ann.Intern.Med.* 119 (2):121-126, 1993.
- W. Q. Wen, X. O. Shu, T. Sellers, S. Bhatia, B. Lampkin, and L. L. Robison. Family history of cancer and autoimmune disease and risk of leukemia in infancy: a report from the Children's Cancer Group (United States and Canada). *Cancer Causes Control* 9 (2):161-171, 1998.
- D. L. Wickerham and E. Tan-Chiu. Breast cancer chemoprevention: current status and future directions. *Semin.Oncol.* 28 (3):253-259, 2001.

- D. L. Wickerham. Tamoxifen - an update on current data and where it can now be used. *Breast Cancer Research and Treatment* 75:S7-S12, 2002.
- D. L. Wickerham. Tamoxifen versus raloxifene in the prevention of breast cancer. *Eur.J.Cancer* 38 Suppl 6:S20-S21, 2002.
- F. M. Wiley, K. Ruccione, I. M. Moore, P. McGuire-Cullen, J. Fergusson, M. J. Waskerwitz, G. Perin, J. Ge, and H. N. Sather. Parents' perceptions of randomization in pediatric clinical trials. Children Cancer Group. *Cancer Pract.* 7 (5):248-256, 1999.
- M. S. Williams, M. Burk, C. L. Loprinzi, M. Hill, P. J. Schomberg, K. Nearhood, J. R. O'Fallon, J. A. Laurie, T. G. Shanahan, R. L. Moore, R. E. Urias, R. R. Kuske, R. E. Engel, and W. D. Eggleston. Phase III double-blind evaluation of an aloe vera gel as a prophylactic agent for radiation-induced skin toxicity. *Int.J.Radiat.Oncol.Biol.Phys.* 36 (2):345-349, 1996.
- M. B. Wilwerding, C. L. Loprinzi, J. A. Mailliard, J. R. O'Fallon, A. W. Miser, C. van Haelst, D. L. Barton, J. F. Foley, and L. M. Athmann. A randomized, crossover evaluation of methylphenidate in cancer patients receiving strong narcotics. *Support.Care Cancer* 3 (2):135-138, 1995.
- N. Wolmark and B. K. Dunn. The role of tamoxifen in breast cancer prevention: issues sparked by the NSABP Breast Cancer Prevention Trial (P-1). *Ann.N.Y.Acad.Sci.* 949:99-108, 2001.
- R. C. Young, M. F. Brady, L. A. Walton, H. D. Homesley, H. E. Averette, and H. J. Long. Localized ovarian cancer in the elderly. The Gynecologic Oncology Group experience. *Cancer* 71 (2 Suppl): 601-605, 1993.



Marcel Conrad, M.D. with wife, Marcia Grove-Conrad, displays Harry Hynes Award for 2003.

HARRY HYNES AWARD

The Community Clinical Oncology Program established the Harry Hynes Award in 2001, to honor Harry Hynes, M.D., principal investigator of the Wichita Community Clinical Oncology Program, for his commitment and dedication to community clinical research.

The Harry Hynes Award has been presented to the following investigators for their outstanding commitment to community clinical research:

2003

Marcel Conrad, M.D.

Gulf Coast Minority-Based Community Clinical Oncology Program

2002

Shaker Dahkil, M.D.

Wichita Community Clinical Oncology Program



Dr. Harry Hynes